Ophthalmology and Therapy Publishes Findings Displaying Way of life-Pushed Rise in Ocular Redness and Differentiated Function of LUMIFY®

Bausch + Lomb Corporation – Business Wire – Tue Feb 24, 6:00AM CST

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a number one world eye well being firm devoted to serving to individuals see higher to stay higher, introduced in the present day that Ophthalmology and Therapypublished a brand new world narrative assessment inspecting the causes, burden and administration of noninfectious conjunctival hyperemia (ocular redness). The assessment highlights the rising world prevalence of ocular redness pushed by digital existence, dry eye, contact lens put on, allergic reactions and environmental components, reinforcing how ocular redness impacts each consolation and look. ¹

Developed by scientific specialists from 9 nations, the publication underscores the aesthetic and psychosocial impression of ocular redness, noting that people with pink eyes could also be perceived as much less wholesome or extra fatigued – a priority amplified by video conferencing and social media, which highlight facial options, together with the eyes and the periocular area. The authors additionally observe that ocular redness often presents signs corresponding to irritation, dryness, itching or foreign-body sensation, contributing to affected person discomfort and diminished high quality of life.

“Ocular redness is no longer just a clinical concern, it’s a global lifestyle and quality-of-life issue,” mentioned Melissa Toyos, MD, lead creator of the assessment and associate, Toyos Clinic, Nashville, Tenn. “Patients today are seeking effective, safe and aesthetically minded products, which makes understanding the differences in products more important than ever.”

Key scientific insights from the paper:

• Rising prevalence: Noninfectious conjunctival hyperemia is rising worldwide because of digital eye pressure, dry eye illness, allergic reactions, contact lens put on and environmental components
• Limitations of conventional decongestants: Traditional α1 and combined α1/α2 decongestants could present short-term symptom reduction however are liable to tachyphylaxis, rebound redness and shorter period of impact
• Impact on consolation and look: Ocular redness is usually accompanied by signs corresponding to irritation and dryness, and should adversely have an effect on high quality of life because of each discomfort and aesthetic issues
• Evidence for brimonidine tartrate 0.025%: Brimonidine tartrate 0.025% (LUMIFY Redness Reliever eye drops), a extremely selective α2-adrenergic receptor (AR) agonist, demonstrated efficient redness discount with no tachyphylaxis over 29 days and just about no rebound redness after discontinuation
• Aesthetic-driven OTC use: Patients more and more search protected OTC redness-relief merchandise for aesthetic causes, highlighting the significance of selective mechanisms and favorable security profiles
• Need for affected person training: Global gaps exist in affected person consciousness and scientific steerage, underscoring the significance of affected person training, acceptable OTC product choice and consciousness of security issues, particularly amid rising world self-treatment and issues with unsafe or unapproved copycat or counterfeit redness relievers

“This publication reinforces the unique, mechanism-based advantages of LUMIFY,” mentioned Mayssa Attar, senior vice chairman, Pharmaceuticals and Consumer R&D, Bausch + Lomb. “The evidence supporting selective α2-AR agonist mechanism clearly differentiates LUMIFY’s established safety and efficacy profile and reflects our commitment to delivering trusted, science-backed products for consumers.”

LUMIFY, formulated with low-dose brimonidine tartrate 0.025%, gives quick, efficient redness discount whereas avoiding tachyphylaxis and rebound redness related to conventional decongestants. Its extremely selective α2-AR agonist mechanism primarily constricts venules somewhat than arterioles, contributing to a good security profile, tolerability and efficacy. Clinical proof throughout 4 trials demonstrated no tachyphylaxis over 29 days and just about no rebound redness upon discontinuation.

The assessment additionally notes a preservative-free formulation of brimonidine tartrate 0.025%, which demonstrated efficacy, security and tolerability corresponding to the unique model with just about no rebound redness. In 2025, Bausch + Lomb launched LUMIFY Preservative Free Eye Drops in handy single-use vials, providing sufferers an extra brimonidine-based choice with out preservatives.

For extra info on LUMIFY and LUMIFY Preservative Free, go to www.lumifyeyes.com .

About Ocular Redness
Ocular redness, or conjunctival hyperemia, is a standard situation that happens when tiny blood vessels on the floor of the attention turn out to be enlarged or irritated, inflicting the attention to seem pink or bloodshot. It will be brought on by components corresponding to digital eye pressure, dry eye illness, allergic reactions, contact lens put on and environmental irritants. Mild redness will be accompanied by irritation or dryness and may impression consolation, look and confidence, prompting many individuals to hunt over-the-counter reduction. ²

About LUMIFY Redness Reliever Eye Drops
LUMIFY is a redness reliever like no different. With its novel mechanism of motion and favorable security profile, LUMIFY has redefined the class and turn out to be an eye fixed care staple – serving to eyes look whiter, brighter and extra stunning. It’s the No. 1 eye doctor-recommended redness reliever eye drop model and holds greater than 60% market share. LUMIFY works in a single minute and lasts as much as eight hours when used as directed. In 2025, Bausch + Lomb launched LUMIFY Preservative Free Eye Drops in handy, single-use vials. For extra info, go to www.lumifyeyes.com .

About Bausch + Lomb
Our mission is straightforward – we assist individuals see higher to stay higher, all around the world. For practically two centuries we’ve advanced with the altering wants of sufferers and clients, and our dedication to innovation and bettering the usual of care in eye well being has by no means been stronger. From contact lenses to prescription merchandise, over-the-counter choices, surgical gadgets and extra, we’re turning daring concepts into higher outcomes by way of ardour, perseverance and function. Learn extra at www.bausch.com and join with us on Facebook , Instagram , LinkedIn , X and YouTube .

References

1. Toyos M, Chan CC, Alio JL, Chong KKL, Pek D, Doan S, Sinjab M, Hosny M, Messmer EM, Giannaccare G. “Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review.” Ophthalmology and Therapy. 2026. .
2. Cleveland Clinic. Red Eye: Causes, Treatment & Prevention. 2023. .

©2026 Bausch + Lomb.
LUM.0051.USA.26

View supply model on businesswire.com: